Antibiotic efficacy is linked to bacterial cellular respiration

The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.

Citation

As Published
http://dx.doi.org/10.1073/pnas.1509743112

Publisher
National Academy of Sciences (U.S.)

Version
Final published version

Accessed
Fri Dec 01 23:52:49 EST 2017

Citable Link
http://hdl.handle.net/1721.1/101114

Terms of Use
Article is made available in accordance with the publisher’s policy and may be subject to US copyright law. Please refer to the publisher’s site for terms of use.

Detailed Terms
Antibiotic efficacy is linked to bacterial cellular respiration

Michael A. Lobritz, Peter Belenky, Caroline B. M. Porter, Arnaud Gutierrez, Jason H. Yang, Eric G. Schwarz, Ahmad S. Khalili, and James J. Collins

Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115; Institute for Medical Engineering & Science, Department of Biological Engineering, and Synthetic Biology Center, Massachusetts Institute of Technology, Cambridge, MA 02139; Broad Institute of MIT and Harvard, Cambridge, MA 02138; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114; Harvard Medical School, Boston, MA 02115; Department of Molecular Microbiology and Immunology, Brown University, Providence, RI 02912; Department of Biomedical Engineering and Biological Design Center, Boston University, Boston, MA 02215; Department of Cell Biology and Molecular Genetics, Institute for Physical Science and Technology, Department of Biomedical Engineering, and Maryland Pathogen Research Institute, University of Maryland, College Park, MD 20742; and Harvard-MIT Program in Health Sciences and Technology, Cambridge, MA 02139

This contribution is part of the special series of Inaugural Articles by members of the National Academy of Sciences elected in 2014.

Contributed by James J. Collins, May 18, 2015 (sent for review November 22, 2014; reviewed by Bruce R. Levin and Evgeny A. Rudler)

Bacteriostatic and bactericidal antibiotics treatments result in two fundamentally different phenotypic outcomes—the inhibition of bacterial growth or, alternatively, cell death. Most antibiotics inhibit processes that are major consumers of cellular energy output, suggesting that antibiotic treatment may have important downstream consequences on bacterial metabolism. We hypothesized that the specific metabolic effects of bacteriostatic and bactericidal antibiotics contribute to their overall efficacy. We leveraged the opposing phenotypes of bacteriostatic and bactericidal drugs in combination to investigate their activity. Growth inhibition from bacteriostatic antibiotics was associated with suppressed cellular respiration whereas cell death from most bactericidal antibiotics was associated with accelerated respiration. In combination, suppression of cellular respiration by the bacteriostatic antibiotic was the dominant effect, blocking bactericidal killing. Global metabolic profiling of bacteriostatic antibiotic treatment revealed that accumulation of metabolites involved in specific drug target activity was linked to the buildup of energy metabolites that feed the electron transport chain. Inhibition of cellular respiration by knockout of the cytochrome oxidases was sufficient to attenuate bacteriostatic lethality whereas acceleration of basal respiration by genetically uncoupling ATP synthesis from electron transport resulted in potentiation of the killing effect of bactericidal antibiotics. This work identifies a link between antibiotic-induced cellular respiration and bacteriostatic lethality and demonstrates that bacteriostatic activity can be arrested by attenuated respiration and potentiated by accelerated respiration. Our data collectively show that antibiotics perturb the metabolic state of bacteria and that the metabolic state of bacteria impacts antibiotic efficacy.

E. coli | S. aureus | antibiotics | cellular respiration | metabolomics

Recent lines of evidence have suggested that antibiotics induce cellular metabolic shifts as a secondary response to their target interaction. The generation of antagonistic metabolic responses may be one possible means by which bacteriostatic and bactericidal antibiotics interact. The predominant cellular process targeted by bacteriostatic antibiotics is translation, which is thought to account for a major portion of the energy consumption in the cell at steady state (23, 24). Consequently, disruption of this process may cause significant changes in cellular energy dynamics (25). In support of this notion, the proteomic response to the bacteriostatic antibiotic chlorotetracycline involves down-regulation of major metabolic pathways (26), potentially suggesting a reduction in metabolic rates. In comparison with the bacteriostatic response, evidence suggests that bactericidal agents may increase cellular metabolic rates and that bacteriostatic antibiotic efficacy may relate directly to metabolic state (27). The transcriptional response to bacteriostatic antibiotics involves up-regulation of genes involved in central metabolism and respiration (28–30). Direct metabolomic profiling of Mycobacterium tuberculosis and Mycobacterium leprae growth in bacteriostatic drug treatments confirms these metabolic effects (31, 32).

Significance

The global burden of antibiotic resistance has created a demand to better understand the basic mechanisms of existing antibiotics. Of significant interest is how antibiotics may perturb bacterial metabolism, and how bacterial metabolism may influence antibiotic activity. Here, we study the interaction of bacteriostatic and bactericidal antibiotics, the two major phenotypic drug classes. Interestingly, the two classes differentially perturb bacterial cellular respiration, with major consequences for their intrinsic activity both alone and in combination. Of note, bacteriostatic antibiotics decelerate cellular respiration, generating a metabolic state that is prohibitive to killing. Further, we show that the efficacy of bactericidal drugs can be improved by increasing basal respiration, and we identify a respiration-related drug target that potentiates the activity of bactericidal antibiotics.


Conflict of interest statement: J.J.C. is a scientific cofounder and Scientific Advisory Board chair of EnBiotix, Inc., a start-up focused on antibiotic development. M.A.L. and P.B. contributed equally to this work.

See OnQs on page 8160.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1509743112/-/DCSupplemental.

www.pnas.org/cgi/doi/10.1073/pnas.1509743112
treated with a range of bactericidal agents demonstrated commonalities in remodeling of central metabolism in response to therapy (31). With regard to cellular metabolic state, the efficacy of bactericidal antibiotic therapy has been linked to carbon flux through the TCA cycle (32, 33), and environmental factors that engage with central metabolism, such as the availability of molecular oxygen to feed the electron transport chain, have also been linked to cell killing by antibiotics (34, 35).

Previous work has indicated that the cellular response to bactericidal antibiotics leads to overflow metabolism and the formation of reactive oxygen species (ROS) as part of their lethality (29, 35, 36), suggesting that accelerated metabolism is a key component of bactericidal activity. Consistent with this hypothesis, we have previously identified divergent effects of bacterial antibiotics and the bactericidal translation inhibitor chloramphenicol on cellular respiration in *Escherichia coli* (35). In the present study, we assess the long-known phenotype of bacteriostatic and bactericidal antibiotic antagonism to address how antibiotics perturb bacterial metabolism and how cellular metabolic state influences antibiotic efficacy. We find that perturbation of cellular respiration is a major byproduct of antibiotic-target interaction. Further, changes in basal rates of cellular respiration can specifically tune the efficacy of bactericidal antibiotics. We identify that bacteriostatic antibiotics generate a metabolic state in bacteria that is prohibitive to killing, which may relate directly to the clinical outcomes identified in combination therapy.

**Results**

**Bacteriostatic Antibiotics Decelerate Cellular Respiration.** To assess physiologic changes induced by bacteriostatic and bactericidal antibiotics at the level of cellular respiration, we used a recently described real-time prokaryotic respiration assay using the Seahorse XF® extracellular flux analyzer (35). This platform measures real-time oxygen consumption rate (OCR) at picomole resolution, which we use as a proxy of cellular respiration (37) (Fig. SL1A). The assay detects oxygen using a solid-state sensor probe in a fluid chamber above a bacterial cell monolayer; thus, oxygen does not need to additionally diffuse through the probe solution matrix. We optimized the assay performance for cell input (Fig. SL1A) and validated that OCR is dependent upon the presence of metabolizable carbon sources (Fig. SL1B).

The assay performed in M9 medium (in *E. coli*) limits growth effects, results in linear increases in OCR over time (Fig. L4), and does not require normalization (35). *Staphylococcus aureus* respiration in minimal media fell below the limit of detection, and thus we adapted the assay to a standard media [tryptic soy broth (TSB)], which demonstrated logarithmic increases in OCR (consistent with more rapid doubling rates) and required normalization using instantaneous live–dead staining (35) (Fig. 1B).

Treatment of *E. coli* with bacteriostatic translation inhibitors resulted in rapid deceleration of cellular respiration (Fig. 1A, Left). This effect was evident as early as 6 min after exposure to drug and was sustained (Fig. 1C1). In contrast, three canonical bacteriostatic antibiotics [ampicillin (Amp), gentamicin (Gent), and norfloxacin (Nor)] accelerated respiration (Fig. 1A, Right) with varying kinetics. Rifampin (Rif), commonly considered bacteriostatic in *E. coli* and bactericidal in *S. aureus* (Fig. S2), potently suppressed OCR in *E. coli* (Fig. 1A, Right). Treatment of *S. aureus* with bacteriostatic translation inhibitors also resulted in rapid inhibition of OCR (Fig. 1B, Upper Left). OCR measurements from bacteriostatic treatment of *S. aureus* without normalization demonstrated distinct dynamics from bacteriostatic antibiotics (Fig. 1B, Lower Left). Normalization for instantaneous live cells yielded accelerated OCR by levofloxacin (Levo) but not daptomycin (Dapt) whereas normalization showed consistent deceleration from chloramphenicol (Cam) treatment (Fig. 1B, Bottom Right). Dapt treatment resulted in very high propidium iodide-positive cells, as expected, due to an increase in cell permeability as a major component of its activity (Fig. SL1D). Rif treatment of *S. aureus*, which exhibits time-dependent killing rather than concentration-dependent killing (Fig. S2), rapidly suppressed OCR in a pattern consistent with other bacteriostatic antibiotics (Fig. 1B, Upper Right).

Thus, bacteriostatic translation inhibitors broadly decelerate cellular respiration whereas most bactericidal antibiotics accelerate respiration. Dapt had a neutral effect on respiration whereas Rif suppressed respiration in *S. aureus* despite killing. We next explored respiration effects caused by antibiotics around the minimum inhibitory concentration (MIC). OCR was monitored in *E. coli* treated with Cam (MIC 6 μg/mL) from 1.5 μg/mL (1/4x MIC) to 24 μg/mL (4x MIC). Deceleration of OCR was maximally achieved at the MIC concentration (Fig. 1C), with no substantial changes by higher concentrations. Sub-MIC Cam resulted in dose-dependent inhibition of OCR (Fig. 1C). In comparison, treatment of *E. coli* with Nor from 12.5 μg/mL (1/4x MIC) to 1 μg/mL (20x MIC) demonstrated dynamic elevations in respiration with maximal acceleration of OCR observed.
at the MIC (Fig. 1C). Interestingly, exposure to subinhibitory concentrations of Nor was sufficient to accelerate cellular respiration (Fig. 1C).

**Respiration-Decelerating Antibiotics Block Lethality of Respiration-Accelerating Antibiotics.** Having observed divergent effects on cellular respiration by bacteriostatic and bactericidal antibiotics, we next assessed the outcome of combination treatments on cell survival. We performed a pairwise lethality screen of 36 clinically relevant bacteriostatic-bactericidal antibiotic combinations in both *E. coli* (16 combinations) and *S. aureus* (20 combinations) by time-kill analysis (Fig. 2 and Fig. S3). We assessed the effect of bacteriostatic treatment before or after bactericidal challenge on cell survival (Fig. 2A and B). Rif did not kill *E. coli* up to 80x MIC (Fig. S2) but did cause robust killing in *S. aureus* with time-dependent kinetics, as opposed to respiration-enhancing antibiotics (Fig. S2).

In *E. coli*, all bacteriostatic antibiotics potently inhibited cell killing by several orders of magnitude, when applied before bactericidal antibiotics (Fig. 2B and C and Fig. S3), and rapidly attenuated killing by bactericidal antibiotics when delivered after 30 min of initial bactericidal exposure (Fig. 2B and C and Fig. S3). No combination of bacteriostatic antibiotics showed killing with Rif in *E. coli* (Fig. 2C and Fig. S3). Similarly, in *S. aureus* we observed broad and potent protection by preincubation with any bacteriostatic antibiotic before bactericidal challenge (Fig. 2D and Fig. S3). Bacteriostatic pretreatment of cells did not offer complete protection from Dapto challenge, consistent with its known effect on membrane integrity and charge-based mode of action (38). We again observed rapid interruption of cell killing after initial bactericidal treatment with any bacteriostatic drug (Fig. 2D and Fig. S3). We observed no impact of any bacteriostatic antibiotic on cell killing by Rif (Fig. 2D and Fig. S3). Taken together, this screen demonstrates that bacteriostatic translation inhibitors generally inhibit killing caused by a wide range of bacteriocidal antibiotics with differing cellular targets. The most notable exception was Rif in our *S. aureus* model, where lethality was not sensitive to bacteriostatic antibiotic cotreatment.

Due to the respiration-decelerating phenotype of Rif, we hypothesized that Rif-mediated killing would be antagonistic to

---

**Fig. 2.** Bacteriostatic antibiotics disrupt bactericidal lethality. (A) Time-kill analysis was performed on *E. coli* or *S. aureus* with bacteriostatic-bactericidal antibiotic pairs. Pretreatment: Bacteria were initially treated with bacteriostatic antibiotics (5x MIC) and subsequently challenged with bactericidal drugs. Posttreatment: Bacteria received initial bactericidal challenge, and bacteriostatic drugs were added second. (B) Representative time-kill analysis of norfloxacin and chloramphenicol combination. In all screens, combination therapy was compared against monotherapy with the single bacteriostatic and bactericidal antibiotic. Survivorship was assessed hourly. Screening of 36 individual antibiotic combinations in *E. coli* (C) and *S. aureus* (D). For both datasets, cell survival was plotted at the 4-h time point as log-change in colony-forming units per milliliter, expressed as percent survival relative to the population at *t* = 0. Bacteriostatic antibiotic monotherapy (black) is listed first. Bacteriostatic monotherapy (red) is followed by pretreatment (white) and posttreatment approaches (light gray). Chloramphenicol (Cam); clindamycin (Clin); erythromycin (Erm); linezolid (Lz); spectinomycin (Spect); Tetracycline (Tet). Error bars represent SEM of three independent experiments. (E) Time-kill curves of *E. coli* treated with norfloxacin, ampicillin, gentamicin, or rifampin monotherapy, compared with pretreatment or posttreatment with rifampin. (F) Time-kill curves of *S. aureus* treated with levofloxacin, gentamicin, daptomycin, or rifampin with rifampin pre- or posttreatment. Curves show mean ± SEM of three independent experiments.
respiration accelerators. Consistent with this proposal, we observed potent protection of *E. coli* by Rif from killing by Nor, Amp, and Gent, and rapid arrest in killing when Rif was added after bactericidal challenge (Fig. 2E), similar to bacteriostatic translation inhibitors. Rif is bactericidal in *S. aureus*; however, due to its time-dependent killing, we could compare Rif killing in combination with concentrations of Levo, Gent, and Dapto that produced more killing by at least an order of magnitude. In combination, we observed that Rif protected against the additional lethality induced by Levo or Gent (Fig. 2F). We did not observe any protection against killing by Dapto, consistent with the lack of respiration acceleration observed for this drug. Thus, Rif, which induces bacteriostatic-like respiratory changes, inhibits the lethality of respiration-accelerating bactericidal antibiotics similar to other bacteriostatic drugs.

**Bacteriostatic Alterations to the Metabolome Correspond to Respiratory Deceleration.** Given the divergent effects of bacteriostatic and bactericidal antibiotics on cellular respiration, we sought to characterize antibiotic-induced metabolic changes more broadly. In particular, we were interested in the dominant effect of respiration-decelerating antibiotics and whether this phenotype was derived from the general metabolic state of the cell. We profiled the metabolome of *S. aureus* treated with the respiration-decelerating antibiotics Cam, Lin, and Rif. We compared untreated cells at time 0 (UT0) with either a growth control (UT30) or cells exposed to antibiotic for 30 min. Our analysis yielded 353 robustly identified metabolites comprising eight superpathways and 63 subpathways (Fig. S4).

Hierarchical clustering of the metabolomics data identified broad trends across treatment conditions (Fig. 3A). We observed a marked progression of metabolism in the untreated sample between the 0-min and 30-min time points (Fig. 3A), reflecting growth during exponential phase. Treatment with the translation inhibitors Cam and Lin yielded indistinguishable metabolic profiles, characterized by elevation in two clusters of metabolites. The first group aligns with elevated metabolites in the UT0 sample and is enriched for amino acids ($P = 2.16 \times 10^{-9}$, hypergeometric test), suggesting an arrest in metabolic progression for these target-specific compounds. The second cluster is enriched for lipids ($P = 1.66 \times 10^{-4}$, hypergeometric test) and shows higher concentrations than either the UT0 or UT30 samples. Rif elicited a unique metabolic response, sharing some aspects of the translation inhibitors, but others that were unique (Fig. 3B).

We noted accumulation of ATP, ADP, and AMP specifically in response to respiration-decelerating antibiotics, consistent with decreased ATP utilization (Fig. 3B and Fig. S5), as well as a significant elevation in NADH, with more modest elevation in NAD+, suggesting a lowered redox state (Fig. 3B). We observed significant elevations in metabolites from central carbon metabolism (Fig. 3C; *Lower Left*), which, coupled to the energy state of the cell, suggested decreased metabolic rates. Further exploration of the metabolomics profiles revealed a striking accumulation of metabolites involved in transcription and translation, the specific targets of the drugs queried (Fig. 3C). Cam and Lin treatment resulted in marked accumulation of amino acids and amino acid precursors, indicative of decreased flux into polypeptide production (Fig. 3C, *Upper Left*). Similarly, Rif induced substantial increases in nucleotide and nucleotide precursors, consistent with inhibition of RNA production (Fig. 3C, *Upper Right*). Interestingly, Rif treatment also induced substantial accumulation of amino acid precursors whereas the translation inhibitors caused accumulation of nucleotides, consistent with the secondary arrest in cell turnover and DNA replication induced by these drugs. All three antibiotics resulted in significant accumulation of lipid and lipid precursors (Fig. 3C, *Lower Right*), which may be due to reduced utilization as an energy source or decreased cell turnover. Taken together, the metabolomics data indicate that inhibition of either transcription or translation results in the accumulation of energy currency and central metabolites coupled to a lower redox state, suggesting the association of reduced rates of respiration with lower overall metabolic rates, which derive from the arrest of a major macromolecular synthetic process.

---

**Fig. 3.** Broad metabolite accumulation observed in bacteriostatic-treated *S. aureus*. In A, B, and C, UT0 represents metabolite levels at the time of antibiotic addition; UT30 represents 30 min of growth in the absence of antibiotics. Cam, Lin, and Rif treatments were assessed 30 min after exposure. (A) Hierarchical clustering of log-transformed and autoscaled relative metabolite concentrations for *S. aureus* treated with bacteriostatic antibiotics vehicle. Five independent experiments are shown as replicates. (B) Box plots of relative concentration values from five independent experiments for ADP, AMP, NAD+, and NADH. (C) Volcano plots showing the fold change (x axis) and significance (y axis) of metabolites detected in the major metabolic pathways. Blue shapes represent metabolites having a fold-change greater than two and *P* value less than 0.05; gray shapes represent metabolites that are not significantly changing. Fold changes are relative to UT30 control and are based on mean values of five independent experiments.
Attenuated Respiration Is Associated with Killing Arrest. Because bacteriostatic and bactericidal antibiotics stimulate competing effects on cellular respiration, we assessed the respiratory outcome of exposure to antibiotics in combination. We measured OCR of E. coli treated with the bacteriostatic antibiotic Cam 30 min before the addition of bactericidal antibiotics (Nor, Amp, Gent) (Fig. 4A). Treatment of cells in series was compared with cells given Cam alone, bactericidal antibiotic alone, or no antibiotic. Cells pretreated with Cam (asterisk) before bactericidal challenge (arrowhead) showed no detectable acceleration in cellular respiration after the addition of the bactericidal drug (Fig. 4A). Similarly, Cam addition after initial bactericidal treatment (arrowhead) resulted in immediate and potent suppression of OCR (Fig. 4B). Similar effects were observed for S. aureus (Fig. S6A). We asked whether prolonged treatment with bactericidal antibiotics would negate the effect of bacteriostatic suppression. E. coli were treated with Nor to initialize cell killing, followed by Cam at 30 or 60 min later. Even at 60 min, Cam addition rapidly attenuated cellular respiration and cell death (Fig. 4C). Similar results were obtained for Amp (Fig. S6B). Independent of the timing of addition, deceleration of cellular respiration driven by the bacteriostatic antibiotic was the dominant phenotype in combination treatment, consistent with the time-kill effect.

Accelerating Basal Respiration Potentiates Bactericidal Killing. The metabolomics data suggested that bacteriostatic inhibition of cellular respiration may be a byproduct of translation inhibition. Inhibition of translation may have additional nonmetabolic effects on the cell that could be the source of attenuated bactericidal activity. To assess whether cellular respiration itself was an important factor in bactericidal activity, we assessed cell killing in a genetic mutant lacking the three major cytochrome oxidases (ΔcyoA ΔcydB ΔappB). This mutant has previously been reported to have reduced rates of cellular respiration (39), which we confirmed in our assay (Fig. 5A). Treatment of cytochrome oxidase null bacteria with norfloxacin resulted in no appreciable acceleration of respiration (Fig. 5A, Right). When we assessed killing by bactericidal antibiotics, we found that the cytochrome oxidase null mutant was highly protected from the lethal effects of Nor, Amp, and Gent (Fig. 5B). Protection from Gent killing is likely related to the breakdown in proton motive force, leading to reduced drug uptake. In addition, consistent with previous results (39), we observed a reduced growth rate of the cytochrome oxidase null mutant relative to the WT, which may have affected its susceptibility to ampicillin.

We further hypothesized that accelerated basal respiration may potentiate killing by bactericidal antibiotics. We sought to uncouple electron transport from ATP production in E. coli. The known inhibitors of the F$_1$F$_0$ ATPase, oligomycin and venturicidin, do not have activity in E. coli whole-cell assays (40). Lacking a chemical approach, we used a knockout of the catalytic domain of the F$_1$F$_0$ ATPase (ΔatpA), which is a nonessential gene given the capacity for fermentative growth. Prior in silico models have predicted an elevated redox state in this mutant (41). We found that the ΔatpA mutant grew at the same rate as WT E. coli but reached stationary phase faster, potentially consistent with reduced efficiency of carbon utilization (Fig. 5C and Fig. S7A). Measurement of the extracellular acidification rate (ECAR) of this strain further confirmed a substantially higher rate of acid secretion, as expected in fermentative growth (Fig. 5E). Interestingly, we observed three-fold elevations in basal OCR in this strain, indicating uncoupling of respiration from ATP production and a compensatory rise in respiration (Fig. 5D). We confirmed that these optical density-matched OCR variations were not due to differences in growth rate, to total cell numbers plated, or to the density of cells in the experiment (Fig. 5F).

Treatment of the ΔatpA strain with Amp and Nor resulted in substantially increased killing (Fig. 5F). We found a leftward shift in the gentamicin minimum bactericidal concentration (MBC) curve, consistent with a likely increase in drug uptake due to elevated proton motive force from altered respiration (Fig. 5F). We were further interested in how bacteriostatic antibiotic treatment may protect against killing in the context of an accelerated basal respiration state. In time-kill analysis, the ΔatpA mutant exhibited approximately two orders of magnitude of increased killing relative to WT (Fig. 5G). Pretreatment with Cam for 30 min, followed by Nor challenge, led to breakthrough killing in the ΔatpA mutant (Fig. 5H). Interestingly, Cam treatment of the ΔatpA mutant decelerates OCR, but with high levels of residual respiration present in this mutant relative to the WT (Fig. 5I). Thus, elevated basal respiration increases killing by respiration-accelerating bactericidal antibiotics.
A key concept supported by this work is that inhibition of anti-biotic targets results in downstream metabolic perturbations. The direction of the shift, however, seems to depend upon the function of the target that is inhibited and is linked to the bacteriostatic or bactericidal outcome. Inhibition of macromolecular synthesis (i.e., transcription or translation) was associated with decreased bacterial cellular respiration. Interestingly, the majority of bacteriostatic antibiotics inhibit protein production (42), which as a process is the largest single consumer of total metabolic output (23, 43). We observed a marked accumulation of amino acids and nucleotides in response to translation and transcription inhibitors, respectively, reflective of reduced incorporation into peptide or RNA chains. In addition, we observed accumulation of amino acid and nucleotide precursors, indicative of bottlenecking of flux from these pools as a direct result of bacteriostatic antibiotic activity. This effect on amino acid and nucleotide metabolism was associated with the accumulation of central carbon metabolites, the flow of which powers the electron transport chain. Prior metabolomic and proteomic analyses of bacteriostatic antibiotic treatments have suggested that central metabolism is suppressed in response to bacteriostatic antibiotic treatment (26, 44). Our data further support this model, suggesting that inhibition of these core cellular processes may reduce energy demand and secondarily suppress rates of cellular respiration and ATP production (25).

On the other hand, most canonical bactericidal antibiotics were associated with accelerated respiratory activity in our study and others (35). It has been hypothesized that bactericidal antibiotics lead to metabolic instability and the formation of toxic ROS as part of their lethality (28, 29, 35, 36). Acceleration of cellular respiration by bactericidal antibiotics may be a potential source of ROS (45). Our work supports this model by showing that tuning rates of basal cellular respiration can significantly impact bactericidal efficacy. What remains unclear is how bactericidal antibiotic target inhibition may lead to acceleration of cellular respiration. Because bacteriostatic antibiotics arrest a metabolically costly process and reduce ATP demand, it is possible that bactericidal antibiotics may aberrantly increase metabolic demand by virtue of their drug–target interaction. In support of this notion, a recent study on the β-lactam mechanism of action revealed that these drugs cause the formation of a futile cycle in the production and degradation of peptidoglycan (46). The formation of a macromolecular futile cycle may accelerate cellular respiration to meet the metabolic demand of dead-end peptidoglycan synthesis. Identification of the mechanism by which β-lactams, quinolones, aminoglycosides, and other bactericidal antibiotics accelerate respiration requires further study.

Under aerobic conditions, *E. coli* uses a branched electron transport chain composed of two NADH-quinone oxidoreductases and three quinol oxidases that efficiently couple electron exchange to ATP production by the *F₅Fo* ATPase (37, 47). Manipulation of the rate of cellular respiration directly by gene knockout resulted in
significant perturbations in bactericidal killing, suggesting a specific role for respiration in antibiotic lethality. Interestingly, several promising antibiotic leads have recently been characterized that target energy production by inhibiting components of the electron transport chain directly (48, 49). The F_{1}F_{0} ATPase is the target of bedaquiline, a novel antibiotic for the treatment of tuberculosis (50, 51). The mechanism of action has largely rested on phenomenological changes in cell state. Our data extend these concepts by demonstrating that these phenotypic outcomes are, in part, a direct reflection of the metabolic perturbation induced by target inhibition. We showed that growth inhibition associated with bacteriostatic antibiotics is linked to suppression of cellular respiration and broader metabolism. Cell death from bactericidal antibiotics, on the other hand, drives acceleration of respiration, and perturbation of the basal level of metabolism significantly impacts the efficacy of bactericidal therapy. Overall, our data support the hypothesis that antibiotics alter the metabolic state of bacteria, contributing to the resulting lethality, stasis, or tolerance, and, further, that the existing metabolic environment of bacteria influences their susceptibility to antibiotics.

**Methods**

**Strains, Media, and Growth Conditions.** *E. coli* K12 strain MG1655 and *S. aureus* strain ATCC 25923 were used in this study. The *E. coli* ΔapdB and ΔapdB ΔappB mutants were constructed by P1 transduction from the Keio collection. *E. coli* was grown in M9 minimal media (Fishier), supplemented with 0.2% casamino acids and 10 mM glucose. *S. aureus* was cultured in tryptic soy broth (TSB) (Trekova). Cells were grown at 37 °C on a rotating shaker at 300 rpm in flasks or at 900 rpm in plate shakers.

**Antibiotics and Chemicals.** *E. coli* cells were treated with bactericidal antibiotics at 5× minimal inhibitory concentration (MIC) (by macrobroth dilution): ampicillin (Amp) 10 μg·mL⁻¹, norfloxacin (Nor) 250 ng·mL⁻¹, gentamicin (Gent) 5 μg·mL⁻¹. Rifampin (Rif) was used at 5× MIC (250 μg·mL⁻¹) for consistency, despite the absence of detectable bactericidal activity. Bacteriostatic antibiotics were used in the screen at 5× MIC unless otherwise indicated: chloramphenicol (Cam) 50 μg·mL⁻¹, erythromycin (Ery) 500 μg·mL⁻¹, spectinomycin (Spect) 200 μg·mL⁻¹, tetracycline (Tet) 10 μg·mL⁻¹. For *S. aureus*, bacteriostatic antibiotics were used at 10× MIC to generate biological equivalents of cell killing, unless otherwise indicated: levofloxacin (Levo) 2 μg·mL⁻¹, Gent 5 μg·mL⁻¹, daptomycin (Dapto) 16 μg·mL⁻¹, rifampin (Rif) 125 ng·mL⁻¹. Daptomycin treatments included 50 μg·mL⁻¹ calcium chloride, as previously reported, for activity (55). Bacteriostatic antibiotics were used, unless otherwise indicated, at 5× MIC: Cam 50 μg·mL⁻¹, linezolid (Lin) 25 μg·mL⁻¹, clindamycin (Clin) 1 μg·mL⁻¹, Erm 5 μg·mL⁻¹. Tet 2 μg·mL⁻¹. All antibiotics were purchased from Sigma.

**Bacterial Respiration.** The XF96 Extracellular Flux Analyzer ( Seahorse Bioscience) was used to quantify oxygen consumption rates (OCR) (35) and extracellular acidification rates (ECARs). An overnight of MG1655 *E. coli* cells was diluted 1:200 into fresh M9 media and grown to an OD_{600} of 0.3. Cells were diluted to 2× the final OD, and 90 μL of diluted cells was added to XF Cell Culture Microplates precoated with poly-o-lysine (PDLL) (35). Cells were centrifuged for 10 min at 1,400 × g in a Heraeus Multifuge x1R (M-20 rotor) to attach them to the precoated plates. After centrifugation, 90 μL of fresh M9 media was added to each well. To assure uniform cellular seeding, initial OCR and ECAR were measured for 5 (7 min) before the injection of antibiotics. *S. aureus* OCR experiments were run in a similar manner, with the exception that the cells were diluted into TSB after the initial LB overnight, and the OCR measurements were similarly run in TSB. Maximal OCR read on the Seahorse was ~700–800 pmol/min, after which point the consumption rate exceeds the replenishment of the system and curve shows a false declination in OCR, which have been excluded from graphical presentation.

**Antibiotics and Chemicals.** *E. coli* or *S. aureus* grown in TSB was normalized to the number of viable cells quantitated using the LIVE/DEAD BacLight Bacterial Viability and Counting Kit-for Flow Cytometry (Life Technologies), according to kit instructions. For this assay, cells were cultured and treated on a parallel XF Cell Culture Microplate and assayed at 30 min after the addition of antibiotics. To prepare cells for measurement, 50 μL of cell culture was added to a 250-μL assay mix (20 μL of fluorescent beads, 10 μL of SYBR green DNA stain, and 180 μL of propidium iodide in a ‘100 mL assay mix’ [150 mM NaCl]) and incubated for 15 min before counting. Measurements were made with a FACS Aria II flow cytometer (Becton Dickinson). The following photomultiplier tube voltages were used: forward scatter (FSC) 200, side scatter 200, fluorescence signal 1A 325, fluorescence signal 2A 390. Acquisition was performed at a low flow rate (~30 events per s), with thresholding on FSC at a value of 1,000.

**Time-Kill and MBC Analyses.** For time-kill analysis, overnight samples of *E. coli* or *S. aureus* were diluted 1:200 into 25 mL of fresh media and grown in a 250-μL baffled flask to an OD_{600} of ~0.2–0.3. Cells were then plated in a six-well dish, and antibiotics were added at the appropriate concentration. At specified time points (30 min for *E. coli*, and 15 min for *S. aureus*), a second antibiotic or vehicle control was added to wells if indicated. The difference in time of addition was related to the determination of the Minimum Bactericidal Concentration (MBC) versus rich media (*S. aureus*). Aliquots of 300 μL were taken at specified times, serially diluted, and spot-plated onto LB agar plates to determine colony-forming units per mL (cfu·mL⁻¹). Dilutions that grew 10–50 colonies were counted. Percent survival was determined by dividing the cfu·mL⁻¹ of a sample at each time point by the initial cfu·mL⁻¹ of that sample.

**Minimum bactericidal concentration (MBC) curves were performed on MG1655, ΔapdB ΔapdB ΔappB, or the ΔapdB mutant.** Overnight cultures were diluted 1:200 in M9 medium and grown to OD 0.2. Cells were exposed to antibiotics at 1.5-fold dilutions for 90 min, and cfu analysis was performed.

**Metabolic Profiling.** *S. aureus* was grown in 100 mL of TSB in 1-L baffled flasks to an OD_{600} of ~0.2–0.3. Control cells were either collected at this time point (UT0), or cells were treated with antibiotics or vehicle. Antibiotics were added for 30 min: linezolid (Lin, 20 μg·mL⁻¹), chloramphenicol (Cam, 50 μg·mL⁻¹), and rifampicin (Rif, 32 ng·mL⁻¹). All samples were collected by centrifugation at 1,400 × g × 5 min at 4 °C, washed in ice cold PBS, and snap frozen in liquid nitrogen before metabolic analysis. Cells were lysed and assayed by Metabolon Inc. as previously described (56).

Relative concentration data for each detected metabolite were normalized by BRADFORD protein concentration and scaled such that the median value across all samples was equal to one. Only robustly identified metabolites, defined as metabolites being identified in at least three out of five of the replicates across all conditions, were retained for analysis. All analyses were then performed in Matlab. The k-nearest neighbors approach, with the standardized Euclidean distance metric, was used to impute missing data. A Welch’s two-sample t test was performed on log-transformed data to evaluate significant changes in metabolite abundance between conditions, and the MetaboMDS function was used for multiple hypothesis testing. Hierarchical clustering (correlation and average were used as the distance and linkage metrics, respectively) and principal component analysis were performed on log-transformed and autoscaled metabolite data. Box plots were constructed in R using normalized relative concentration data. To determine pathway enrichment, the hydecd function was used to perform a hypergeometric test in Matlab. ATP concentrations, which were not detected on the Metabolon platform, were determined using a bio-diluromass assay (Sigma), with ATP concentration corrected by total protein as determined by BCA assay (Pierce).

**ACKNOWLEDGMENTS.** This work was supported by the Howard Hughes Medical Institute (J.J.C.), National Institutes of Health Director’s Pioneer Award DP5OD003644 (to J.J.C.), and a Merieux Research Grant from the Institut Merieux (to A.S.K. and J.J.C.). M.A.L. is supported in part by the Clinical Fellows program from the Wyss Institute at Harvard University.


